Utilization of Upadacitinib in the treatment of Crohn's disease: a report on two clinical cases

• Autores: Quera, Rodrigo, Córdova, Andrea, Núñez, Paulina, Correa, Ismael, Flores, Lilian
• Formato: artículo
• Fecha de Publicación: 2024
• Institución: Sociedad de Gastroenterología del Perú
• Repositorio: Revista de Gastroenterología del Perú
• Lenguaje: español
• OAI Identifier: oai:ojs.revistagastroperu.com:article/1686
• Enlace del recurso: https://revistagastroperu.com/index.php/rgp/article/view/1686
• Nivel de acceso: acceso abierto
• Materia: Enfermedad de Crohn; Enfermedades inflamatorias intestinales; Quinasas janus; Tratamiento; Crohn disease; Inflammatory bowel diseases; Janus kinases; Treatment

Crohn’s disease (CD) is a chronic, progressive inflammatory disease with complications that impact the well-being of patients. The therapeutic advances achieved in recent decades, especially through the advent of biological therapy, have allowed for a transformation in the approach and management of CD, thereby modifying the course of this disease. However, a significant number of patients do not experience a satisfactory response to these drugs or lose it during the course of the disease. In this scenario, a viable alternative is to switch medications. Upadacitinib, a novel Janus  kinase inhibitor, has emerged as a promising strategy for the management of CD. We  presented two cases of patients with CD refractory to conventional therapy and biological therapy, who responded successfully to treatment with upadacitinib.